文献速递急性肾损伤血液净化与透析

终身依库珠单抗治疗与非典型溶血性尿毒症综合征疾病监测的成本效益比较

Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

该经济评价基于SETS aHUS试验结果,采用马尔可夫模型评估长期停用依库珠单抗并转为疾病监测策略的成本效益。相比终身依库珠单抗治疗,撤药监测策略使患者平均QALYs增加0.08(95%CrI -0.33至0.53),患者费用减少4 234 196英镑(95%CrI -684 495至-6 403 694英镑),生存影响小,80年时间跨度内平均减少0.0005患者生命年(95%CrI -0.0029至0)。撤药监测策略有64%的可能性更具成本效益。

要点

  • 撤药监测策略较终身依库珠单抗治疗平均增加0.08 QALYs,患者费用减少4 234 196英镑。
  • 撤药监测策略在80年时间跨度内平均减少0.0005患者生命年,对生存影响小。
  • 撤药监测策略有64%的可能性比终身治疗更有效且成本更低。

核心结论

  • 撤药监测策略与终身依库珠单抗治疗相比具有成本效益,预计可大幅降低每例患者费用,并可能改善患者平均生活质量。

研究设计与样本

  • 采用马尔可夫模型估算长期撤药监测策略的成本和质量调整生命年(QALYs),以SETS aHUS试验结果为依据,包括复发诊断或进展风险、效用值和额外医疗使用,复发诊断时间采用参数生存函数外推。

主要发现

  • 撤药监测策略使患者平均QALYs增加0.08(95%CrI -0.33至0.53),患者费用减少4 234 196英镑(95%CrI -684 495至-6 403 694英镑),相比终身依库珠单抗治疗。
  • 撤药患者在80年时间跨度内平均减少0.0005患者生命年(95%CrI -0.0029至0),对生存估计影响小。
  • 撤药监测策略有64%的可能性比终身治疗更有效且成本更低,结果在多个探索不确定性的情景中保持稳健。

关键数值与推荐

  • 撤药监测策略相比终身依库珠单抗治疗:QALYs增加0.08(95%CrI -0.33至0.53),患者费用减少4 234 196英镑(95%CrI -684 495至-6 403 694英镑),生命年减少0.0005(95%CrI -0.0029至0),更具成本效益的可能性为64%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is a rare but severe condition caused by complement dysregulation. Eculizumab prophylaxis prevents recurrence and improves survival, yet the benefits of lifelong treatment for patients are uncertain and the long-term costs for health services are substantial. This economic evaluation applied the results from the Stopping Eculizumab Treatment Safely in aHUS (SETS aHUS) trial and assessed the cost-effectiveness of replacing lifelong eculizumab with a disease monitoring strategy over the long term. METHODS: A Markov model was used to estimate cost and quality-adjusted life years (QALYs) for a treatment withdrawal and disease monitoring strategy over the long term. Results from the SETS aHUS trial informed the risk of relapse diagnosis or progression, utility values and additional healthcare use. Time to relapse diagnosis was extrapolated using parametric survival functions. RESULTS: The treatment withdrawal and disease monitoring strategy increased average patient QALYs by 0.08 [95% credible interval (CrI) -0.33-0.53], and reduced patient costs by £4 234 196 (95% CrI -£684 495 to -£6 403 694) compared with the lifelong delivery of eculizumab. The impact on survival estimates was low, as withdrawal patients had an average reduction of 0.0005 patient life years (LYs) (95% CrI -0.0029-0) over an 80-year time horizon. Withdrawal and monitoring had a 64% likelihood of being more effective and less costly than lifelong treatment. Results remained robust across multiple scenarios exploring uncertainties. CONCLUSION: Treatment withdrawal and disease monitoring was cost-effective compared with lifelong eculizumab therapy. Its adoption is expected to substantially reduce costs per patient and may improve average patient quality of life.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Orozco-Leal G, Vale L, Oluboyede Y, et al. Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS. Nephrol Dial Transplant. 2026. PMID: 40844834. doi:10.1093/ndt/gfaf166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。